East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP, 5 mg/2.5 mg. Aurobindo Pharma’s Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Librax® Capsules manufactured by Bausch Health US, LLC.

Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules are indicated:

• To control emotional and somatic factors in gastrointestinal disorders
• Adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.